TD Cowen lowered the firm’s price target on Gilead to $90 from $95 and keeps an Outperform rating on the shares. The firm noted HIV and oncology were weak while Veklury more than offset and OpEx was higher than expected. Ex-Veklury, they believe the base business product sales growth guidance of 5% is likely conservative.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GILD:
- Options Volatility and Implied Earnings Moves Today, February 06, 2024
- GILD Earnings this Week: How Will it Perform?
- Gilead Sciences Elects New Board Member and Audit Committee Participant
- Biotech Alert: Searches spiking for these stocks today
- FDA approves manufacturing process change for Kite’s Yescarta for TAT reduction